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Paragraph (200 words allowed, at 196) 
The targeted delivery of a therapeutic directly to tumor cells in vivo is of immense importance 
in the treatment of cancer, as most current cancer therapies have deleterious effects on healthy 
organ systems. The development of alternative therapies, such as those based on replacement 
of a tumor suppressive miRNA, are equally important given the relative ease at which many 
cancers develop multi-drug resistant phenotypes. Here, we demonstrate the first nanoparticle-
based targeted delivery of a tumor suppressive microRNA, miR-34a
1-4
, to neuroblastoma 
tumors in a murine orthotopic xenograft model
5
. Neuroblastoma is often a treatment-
refractory paediatric cancer originating from precursor cells of the sympathetic nervous 
system
6
, with tumors expressing high levels of the cell surface antigen disialoganglioside 
GD2 (GD2). Mesoporous silica nanoparticles conjugated to a chimeric GD2 antibody (GD2-
Ab ch14.18) and encapsulating mature miR-34a sequences permitted tumor-specific 
endocytosis following systemic administration to the mouse model. Intra-cellular release of 
miR-34a resulted in the induction of caspase-mediated apoptosis through targeting of 
numerous genes associated with cell proliferation and apoptosis and a significant decrease in 
tumor growth.  These novel findings highlight the potential of GD2-nanoparticle-mediated 
specific delivery of miR-34a and other therapeutics to neuroblastoma and potentially other 






Main body  
     Neuroblastoma is the most common extra cranial tumor in childhood, displaying extreme 
heterogeneity in clinical behaviour, ranging from spontaneous tumor regression to 
development of a high degree of resistance to standard chemotherapeutic treatments and 
fatality. MicroRNAs (miRNAs), which negatively regulate gene expression at a post-
transcriptional level, are highly associated with aggressive disease pathogenesis and represent 
potential novel therapeutic targets
7-9
. In this regard, a number of miRNAs are known to 
induce apoptosis or differentiation when ectopically over-expressed in neuroblastoma cells
4,10-
11
. Although miRNA mediated therapeutics has been the subject of many reviews
12
, the 
successful application of miRNAs as a cancer therapy in vivo is limited
13-17
. Here, we 
demonstrate the targeted delivery of miR-34a to neuroblastoma tumors using a 
disialoganglioside GD2 (GD2)-antibody conjugated to the surface of nanoparticles 
systemically administered to a murine orthotopic xenograft disease model.  
     GD2 is a galactose-containing cerebroside found on the cell surface membrane of central 
nervous system tissue that is highly expressed on the cell surface of several human cancers
18
,  
providing a potential target for immunotherapy
19-21,22
 and a possible mechanism for targeted 
delivery of therapeutics. Development of a human/mouse chimeric GD2 antibody (ch14:18) 
led to reduction of immunogenicity in patients
23-25
. Although use of GD2-Ab ch14.18 as a 
targeting antibody for liposome-mediated therapeutic delivery has previously been evaluated 
in an in vitro model
26
, the main disadvantage of standard liposome formulations in vivo is 
their rapid uptake by the reticuloendothelial system, primarily in the liver. In this study, we 
evaluated mesoporous silica-based nanoparticles
27
 which are considered a more stable and 
inert delivery vehicle. 
     The use of GD2 conjugated nanoparticles as a stable system for targeted delivery of miR-
34a was extensively evaluated by in vitro studies prior to use in a published murine orthotopic 
 4 
xenograft model of neuroblastoma
5
. The in vivo model utilizes two cell lines which stably 
express luciferase, NB1691 (MYCN amplified) and SK-N-AS (non-MYCN amplified). Both 
of these cell lines, along with a negative control cell line, HEK293 (embryonic kidney origin), 
were initially assessed by fluorescence activated cell sorting for GD2 expression. FACS 
analysis indicated that GD2 expression was significantly higher in the two neuroblastoma cell 
lines relative to HEK293 (Fig. 1a-c). In order to determine if GD2 conjugated nanoparticles 
would be taken up by GD2 expressing cells at greater specificity than GD2 negative cells, 
NB1691 and HEK293 were treated with different concentrations of GD2 conjugated 
nanoparticles tagged with a FITC fluorochrome reporter. Four hours after treatment, cells 
were washed and FITC fluorescence was measured using a Viktor Microplate luminometer. 
At concentrations of 6.8x10
9
 particles/ml, uptake was approximately 7.6 fold higher in 
NB1691 cells relative to HEK293 (normalised to non-coated FITC-doped nanoparticle) (Fig. 
1d). Notably, higher concentrations of GD2-FITC-NPs saturated both NB1691 and HEK293 
cells, indicating that specificity was dependent upon the concentration of GD2-FITC-NPs.  
     In order to evaluate whether miRNAs encapsulated within nanoparticles would be released 
into the cellular cytoplasm after endocytotic uptake, we constructed GD2-conjugated 
nanoparticles encapsulating either miR-34a or a scrambled negative oligonucleotide. 
Treatment of NB1691, SK-N-AS and HEK293 cells in vitro with 6.8x10
9
 particles/ml resulted 
in a significant up-regulation of miR-34a in the neuroblastoma cell lines, but not in HEK293, 
(Fig. 1e)  indicating targeted delivery and release of the nanoparticle contents to GD2 
expressing cells.  Moreover, the release of miR-34a in NB1691 and SK-N-AS cells resulted in 
a significant increase in caspase 3/7 activation (Fig. 1f p<0.05) and a decrease in cell 
viability, as determined by both an acid phosphatase assay (Fig. 1g-h p<0.001) and cell 
counting (Supplementary Fig. 1). No apoptotic response was detected for HEK293 cells, due 
to the specificity of the GD2-NPs for GD2 expressing cells. To confirm that HEK293 cells are 
 5 
susceptible to miR-34a induced apoptosis, miR-34a was introduced into these cells using a 
reverse transfection method (Supplementary Fig. 2). We also determined that other cell lines 
of non-malignant origin, such as IMR-90 fibroblasts are also adversely affected by miR-34a 
(Supplementary Fig. 3), providing a rationale for the development of a system for targeted 
delivery in vivo.  
      Given that our in vitro studies indicated that a final concentration of 6.8x10
9
 particles/ml 
resulted in specific delivery to GD2
 
expressing cells and an apoptotic response, a similar 
initial concentration was used for in vivo analysis (3.4x10
10
 particles/mouse provides an 
estimated 6.8x10
9
 particles/ml based on the assumption that an average mouse (20g) 
possesses a circulating blood volume of 1.2ml or 60ml/kg
28
). FITC-GD2-NPs were 
systemically administered to tumor bearing mice at day 14, after tumor establishment had 
been verified. The mean fluorescence intensities of tumors were 6.7 to 258 fold greater than 
in healthy organs (liver, spleen, kidney, lung and heart) scanned ex vivo (Fig. 2b).  Among the 
normal organs, FITC signal was highest in liver, which could potentially be due to the 
detoxification function of this organ. The mean fluorescence intensity of tumors from mice 
injected with FITC-GD2-NPs was 13.85 fold higher (Fig. 2c p<0.05) than tumors from mice 
injected with FITC-nanoparticles lacking GD2, further confirming targeted delivery.  
     Given the success of our in vivo targeting experiments, we then evaluated GD2-coated 
nanoparticles as a means of targeted delivery of miR-34a as a potential therapeutic to 









 tumor bearing mice were systemically administered either 
GD2-miR-34a-NP or GD2-miRneg-NP (containing a scrambled oligonucleotide) at day 14, 17 
and 20 post-tumor establishment. Ultra-sonography and bioluminescence analysis, prior to 
nanoparticle injection (day 13 post-tumor induction), indicated equivalency of tumor sizes in 
miR-34a versus negative control treated populations (Supplementary Fig. 4). Tumors were 
 6 
then monitored on days 18, 21 and 25 by bioluminescent imaging (Fig. 3a-d).  




 tumor bearing mice injected with 
GD2-miR34a-NP was significantly reduced relative to mice injected with GD2-miRneg-NP 
(p<0.05 for both tumor types). Measurements of post-mortem tumor volumes and weights 
(day 25) confirmed the highly significant reduction in tumor growth in GD2-miR34a-NP 
treated mice (Supplementary Fig. 5). 





tumors treated with GD2-miR34a-NP relative to those treated with GD2-miRneg-NP (Fig. 
3e,f; respectively,p<0.05 and p<0.001). Interestingly, two of the SK-N-AS
luc
 tumors exhibited 
no increase in miR-34a levels, and these two tumors correspond to two outlier tumors (Fig. 
3d) which grew somewhat faster than the main tumor cohort, the most likely explanation 
being that one or more of the tail vein injections failed on these two mice.  
      qPCR analysis also indicated a significant decrease in mRNA levels for the validated 
miR-34a target oncogene, MYCN in the NB169
luc
 tumors (MYCN amplified) (Fig. 3g 
p<0.001). Although not statistically significant, there was also a trend towards MYCN 
reduction in the non-MYCN amplified SK-N-AS
luc
 tumors (Fig. 3h). The decreased MYCN 
mRNA in NB1691
luc
 tumors was further validated at protein level by western blot (Figures 3i 
and j). TUNEL staining of paraffin embedded tumor sections showed significantly increased 




 tumors treated with GD2-miR34a-NP relative to 
GD2-miRneg-NP (Fig. 4a-c). Immunohistochemical staining of tumor sections with other 
markers, notably, CD34 (a marker of vascularisation) and KI67 (proliferation) displayed a 
significant reduction in vascular endothelial cells (Fig. 4d-f) and results for KI67 (Fig. 4g-i); 
respectively. 
Evaluation of non-specific delivery of miR-34a to normal organs was paramount to 
ensuring specific targeting of the GD2-NPs to the neuroblastoma tumor.  In this regard, liver, 
 7 
kidneys and lungs were assessed for possible increases in endogenous levels of miR-34a after 
treatment with GD2-miR34a-NPs.  All organs assessed did not exhibit any significant increase 
in mature miR-34a transcript levels subsequent to treatment, relative to GD2-miRneg-NP 
treated controls (Supplemental Fig. 6).  Blood chemistries were analysed in GD2-miRneg-NP 
and GD2-miR34a-NP-treated animals to evaluate the effects, if any, administration of 
mesoporous silica nanoparticles might have on the animal.  From the data analysed 
(Supplementary Fig. 7) systemic tail vein injection of either miR-negative control or miR-
34aÐGD2-nanoparticles did not appear to cause significant adverse effects on kidney and/or 
liver function.   
Recently, non-targeted lipid based delivery of miR-34a was shown to have anti-
tumorigenic effects on a mouse xenograft model of prostate cancer, with the authors 
suggesting that the miR-34a formulation was successfully tolerated by mice
29
. Targeting of 
miRNA therapeutics, however, could be of far greater importance in humans with longer life 
spans, and especially as a potential therapeutic for children with developing organs. Here, we 
have shown that over-expression of miR-34a in cell lines of non-malignant origin causes 
significant apoptosis, and one might expect this miRNA to have similar adverse effects on 
proliferating healthy cells in vivo. The efficacy with which GD2-NP-mediated delivery of 





tumor models, provides evidence for the potential use of miRNA-mediated therapeutics in 
neuroblastoma and potentially other cancers, such as melanoma or small cell lung carcinoma, 
that express high levels of the surface antigen GD2.   
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Figure Legends 
Figure 1 In vitro analysis of GD2 conjugated nanoparticles. (a) FACS analysis, using a GD2 
primary antibody and goat anti-mouse IgG2a-PE secondary antibody indicated little, if any, 
GD2 surface antigen on HEK293 cells.  Conversely NB1691 (b) and SK-N-AS (c) cells 
showed significant GD2 reactivity. (d) Varying concentrations of FITC-GD2-NPs were added 
to cell culture media of NB1691 or HEK293 (1x10
6




particles/ml was found to be the optimal dosage tested for specific delivery of FITC 
fluorophore to NB1691 neuroblastoma cells with minimal incorporation into HEK293 cells.  
(e) GD2-miR34a-NPs treatment led to ~2 fold increase in miR-34a levels in NB1691 cells, 
~30 fold increase in SK-N-AS cells (* p<0.05, n=3),   with no significant change in miR-34a 
transcript levels in HEK293 cells. (f) NB1691 and SK-N-AS cells showed a significant 
increase in caspase 3/7 activity relative to GD2-miRneg-NP-treated cells after 72 hrs 
(*p<0.05, n=3) while HEK293 cells showed no significant increase in caspase activity under 
these conditions. Acid phosphatase assays indicated a significant reduction in viable cell 
numbers for (g) NB1691 and (h) SK-N-AS cells treated with GD2-miR34a-NPs (6.8x10
9
 
particles/ml), over a 96 hour period (***p<0.001) relative to GD2-miRneg-NP-treated 
controls. (i) HEK293 cells showed no significant reduction of viable cells following treatment 
with GD2-miR34a-NP (p>0.05, n=3). 
 
Figure 2 Demonstration of tumor specific targeting by systemically administered GD2 
conjugated nanoparticles tagged with FITC. (a) Systemic administration through lateral tail 
injection of FITC-GD2-NPs (3.4x10
10 
particles/200µl) resulted in targeted delivery of FITC 
dye predominantly to tumors (indicated by fluorescence intensity color map generated from 
scans using IVIS instrumentation). (b) FITC-GD2-NP-treated organs have significantly less 
fluorescence than isolated tumors (*p<0.05, n=4-5) and (c) FITC-GD2-NP treated tumors 
showed significantly greater presence of FITC dye relative to FITC-NP treated tumors 
(*p<0.05, n=4-5).  
 
Figure 3 In vivo analysis of GD2 conjugated nanoparticles bearing miR-34a or negative 
control oligonucleotide. Bioluminescent images representative of mice bearing (a) NB1691
luc
 
tumors treated with GD2-miRneg-NP (left) or GD2-miR34a-NP (right), along with 
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representative mice bearing (b) SK-N-AS
luc
 tumors treated with GD2-miRneg-NP (left) or 
GD2-miR34a-NP (right) were obtained at day 25. Tumor growth curves from (c) mice bearing 
NB1691
luc
 tumors treated with GD2-miRneg-NP (black line) or GD2-miR34a-NP (red line) 
and (d) mice bearing SK-N-AS
luc
 tumors treated with GD2-miRneg-NP (black line) or GD2-
miR34a-NP (red line). Time points for systemic administration of nanoparticles are indicated 
by the symbol ▲. Differences in tumor growth between mice injected with GD2-miR34a-NP 





 *p<0.05 for n=8 and **p<0.01 for n=6).  For the SK-N-AS
luc
 model, 
two tumors grew significantly faster than the median, potentially indicating failure of one or 
more tail vein injections. Mature miR-34a transcript levels were significantly higher in GD2-
miR34a-NP treated tumours relative to GD2-miRneg-NP-treated control tumors in both the (e) 
NB1691
luc
 (***p<0.001, n=8) and (f) SK-N-AS
luc
 (*p<0.05, n=8). (g) MYCN, a validated 
target of miR-34a, mRNA levels were significantly reduced in GD2-miR34a-NP treated 
NB1691
luc
 tumors relative to negative controls (**p<0.001, n=8) (h) qPCR of SK-N-AS
luc
 
tumors showed a trend in reduction of MYCN expression (i) MYCN reduction in NB1691
luc
 
was validated at a protein level by Western Blot and (j) protein suppression was quantified 
using densitometry. 
 
Figure 4 Analysis of tumors treated with miR-34a and negative control oligonucleotides.  
TUNEL staining was carried out on paraffin embedded section of SK-N-AS
luc
 (a) and 
NB1691
luc
 (b) tumors.  In both tumor subtypes, treatment with GD2-miR34a-NPs led to a 
significant increase in apoptosis (c, ***p<0.0001, n=8).  Immunohistochemistry staining with 
CD34 showed a marked decrease in the endothelial cell marker subsequent to GD2-miR34a-




     Cell Lines. NB1691 and SK-N-AS cells were maintained in RPMI-1640 supplemented 





cell lines were also supplemented with 100µg/mL Zeocin (InVivoGen, San 
Diego, California). HEK293 cells were grown in DMEM supplemented with FBS (10%) and 
l-glutamine (1%). Each cell line was validated by aCGH profiling for identification of 
previously published genomic abnormalities.  
     Reverse transcription, Real-time qPCR and Western Blotting. Total RNA was 
extracted using a miRNeasy© kit (Qiagen Inc, Valencia, CA). Reverse transcription was 
carried out using 50ng of total RNA with a primer specific for miR-34a, or random primers 
for gene expression, and the TaqMan reverse transcription kit (Applied Biosystems). qPCR 
was carried out on the 7900 HT Fast Real-time System (Applied Biosystems). β-actin, was 
used for normalization. A relative fold change in expression of target miRNA/gene transcripts 
was determined using the comparative cycle threshold method (2
-ΔΔCT
). Total protein was 
isolated from cells using a radioimmunoprecipitation assay (RIPA) lysis buffer (Sigma-
Aldrich Corp., St. Louis, MO).  Protein concentration was measured using the BCA assay 
from Millipore. Proteins were fractionated on 10% polyacrylamide gels and blotted onto 
nitrocellulose membrane.  The membrane was probed with Anti-MYCN antibody (n-mycn: 
Santa Cruz (SC-53993), 1:500) or anti a-tubulin (Abcam (AB7291), 1:5000 used for loading 
controls).  Signal was detected using Immoblion Western (Millipore) and densitometry was 
determined using the ImageJ processing program
30
. 
     Fluorescence Activated Sorting Analysis. Log phase cells (2x10
6
) were harvested and 
stained with GD2 primary antibody (Santa Cruz, sc-53831) and a goat anti-mouse IgG2a-PE 
secondary antibody (Santa Cruz, sc-3738).  Cells were then collected (1x10
3
) and analyzed by 
FACS Calibur (BD Bioscience). 
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     Synthesis of FITC dye doped silica nanoparticle; empty or containing either miR-34a 
or a miR-negative control: All chemicals were obtained from Sigma Aldrich, (Sigma-
Aldrich Corp., St. Louis, MO) unless otherwise stated.  Silica nanoparticles containing 
fluorescein (3 (w/w)) and synthetic premiR-34a (0.1 (w/w)), or a scrambled miR-negative 
control (0.1 (w/w)), were prepared using a microemulsion method
31
.        
Conjugation of GD2-Ab ch14.18 to the nanoparticles. Conjugation was performed 
in duplicate for nanoparticles containing miR-34a or a miR-negative control, according to a 
previously published protocol using PAMAM dendrimers
32
. The NPÐantibody bioconjugates 
were aliquoted (0.1mg) and later re-suspended in sterile cell culture media immediately prior 
to use. In parallel, FITC-only doped GD2-NPs were also synthesized using the 
aforementioned protocol. 
     MicroRNA and nanoparticle treatment of NBL cells in vitro. The Pre-miRª to miR-
34a (30µM) and the premiR-negative control miRNA (negative control 1, Applied 
Biosystems) were reverse transfected into NB1691, SK-N-AS and HEK293 cell lines using 
the transfection agent siPORTª NeoFXª (Applied Biosystems/Ambion, Austin, TX). For 
nanoparticle experiments, NB1691, SK-N-AS and HEK293 cell lines were seeded at the 
required confluency 24 hours prior to treatment.  Each vial of freeze-dried nanoparticles 
(1.7x10
11
 particles) was resuspended in pre-warmed cell culture media (1ml) and protected 
from the light (stock solution of nanoparticles 1.7x10
11
 particles/ml). The final concentration 
used was 6.8x10
9
 particles/ml.   
     Fluorescence analysis. Following treatment with FITC doped nanoparticles, cells were 
lyzed using a RIPA buffer and centrifuged at 14,000rpm for 15 minutes at 4¡C.  The relative 
fluorescent units (RFUs) of isolated supernatant (50µl) was then detected using a Viktor 
Microplate luminometer (Molecular Devices, Sunnyvale, CA). 
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     Acid phosphatase assays.  Cells were transfected in 96-well plates (1x10
4 
cells per well). 
At designated time points post-treatment, cells were washed with PBS and 10mM p-
nitrophenol phosphate in sodium acetate (0.1M) with triton X-100 (0.1%) being added. Plates 
were incubated at 37¡C for two hours in the dark and the reaction was stopped with sodium 
hydroxide (50µl 1M) per well. Absorbance was measured at 405nm.  
     Caspase 3/7 activity assay. NB1691, SK-N-AS and HEK293 cells were plated in 
quadruplicate in 96-well plates. 72 hours after nanoparticle treatment or miRNA transfection,  
caspase activity was measured using the 3/7 Caspase detection kit from Promega (Madison, 
WI) in accordance with manufacturers protocols. Luminescence was read on a Viktor 
Microplate luminometer (Molecular Devices, Sunnyvale, CA).  
     In vivo targeting and nanoparticle delivery. All animal experiments were carried out 
using CB-17/SCID mice (CharlesÕ River Laboratories, Wilmington, MA) and were performed 
in accordance with a protocol approved by the Institutional Animal Care and Use Committee 
of St Jude ChildrenÕs Research Hospital, Memphis, Tennessee. Retroperitoneal tumors were 






 cells behind the left adrenal gland 
via a left subcostal incision under administration of isoflurane (2%), and tumors were allowed 
to develop over 13 days (n=8 per cohort). 3.4x10
10
 nanoparticles/mouse (either fluorophore-
doped-GD2-coated NPs, fluorophore-doped-NPs, GD2-miR34a-NPs, or GD2-miRneg-NPs-
treated) were administered via lateral tail vein injection to mice with pre-established 
retroperitoneal neuroblastoma (day 21 for the targeting experiments with FITC doped 
nanoparticles; day 13 for the microRNAs bearing nanoparticles. Scanning of resected tumours 
and organs ex vivo or of tumors in vivo was performed using an IVIS Imaging System 100 
Series (Xenogen Corporation, Alameda, CA). For experiments using nanoparticles bearing 
miR-34a or a negative control oligonucleotide, animals in each cohort were tumor size 
matched using ultrasound and bioluminescent imaging, and each cohort received repeat 
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injections with GD2-miRneg-NPs or GD2-miR34a-NPs (3.4x10
10
 particles/mouse) at 3 day 
intervals (days 14, 17 and 20 post-tumor induction).  For imaging, mice received an 
intraperitoneal injection of D-Luciferin (150-mg/kg, Caliper Life Sciences, Hopkinton, MA).   
     Tumor Immunohistochemistry. Formalin-fixed, paraffin-embedded, 4-µm thick tumor 
sections were stained with rat antimouse CD34 antibody (RAM 34; PharMingen, San Diego, 
Calif) or KI67 (CAT no.).  TUNEL staining was carried out in accordance with previously 
published protocols
33




     Statistical analysis. The Mann-Whitney non-parametric, one-tailed unpaired test was used 
to analyze significance of change in tumor bioluminescence over time, post-mortem tumour 
analysis of miR-34a expression by qPCR, mean cell viability, caspase activation and cell 
numbers at final time points in individual experiments (all data is plotted as the median + 
standard error of the mean). 
     Abbreviations. Quantitative PCR (qPCR), Fluorescein 5(6)-isothiocyanate(FITC); 
aminopropyltrimethoxysilane (APTMS); tetraethylorthosilicate(TEOS); 3-
(Trihydroxysilyl)propyl methylphosphonate, monosodium salt solution (THPMP); Poly-
amidoamine (PAMAM); 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride 
(EDC); N-hydroxysulfosuccinimide (sulfo-NHS); 2-(N-morpholino)ethanesulfonic acid 
(MES) 
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